Molbio Diagnostics Q1 FY27: Revenue ₹411.48 Cr, PAT ₹52.74 Cr, EBITDA ₹103.68 Cr
Molbio Diagnostics reported Q1 FY27 unaudited results with Total Income at ₹411.48 Cr, up from ₹100.47 Cr in Q1 FY26. EBITDA was ₹103.68 Cr (vs. loss of ₹14.50 Cr) and PAT was ₹52.74 Cr (vs. loss of ₹23.94 Cr). Truenat test-kit volume drove growth.
The announcement details a strong financial performance with significant improvements in revenue and profitability, indicating a positive trajectory for the company post-listing.
The company has shown a significant turnaround in profitability, moving from losses in the previous year's comparable quarter to substantial profits in the current quarter. Revenue and key metrics like EBITDA and PAT have shown strong positive growth.
Molbio Diagnostics Limited announced its unaudited financial results for the first quarter of FY27, ending June 30, 2026. The company reported a Total Income of ₹411.48 Cr, a significant increase from ₹100.47 Cr in the same quarter of the previous fiscal year (Q1 FY26). This growth was primarily driven by the continued volume of Truenat test-kit consumption.
The company achieved an EBITDA of ₹103.68 Cr in Q1 FY27, a substantial turnaround from a loss of ₹14.50 Cr in Q1 FY26. The EBITDA margin stood at 25.20%, reflecting operating leverage from rising test-kit volumes, partly offset by investments in international market expansion.
Profit After Tax (PAT) for the quarter was ₹52.74 Cr, compared to a loss of ₹23.94 Cr in Q1 FY26. The PAT margin was recorded at 12.82%. The company noted that its business has a non-linear revenue profile, and performance should be assessed on a full-year basis. Certain export orders of approximately ₹57 Cr, originally pertaining to Q4 FY26, were deferred due to regional situations and recognized in Q1 FY27.
Key operating metrics show that 6.24 million Truenat test kits were sold in Q1 FY27, compared to 0.79 million in Q1 FY26. The domestic revenue mix was 83.52% and export revenue mix was 16.48% in Q1 FY27.
Management highlighted that the company has sufficient capacity headroom for volume-led scale-up without near-term incremental capex. The pipeline of 34 additional assays across 22 diseases remains on track. Molbio Diagnostics is expanding its international presence in Africa and Southeast Asia, entering Latin America, and progressing regulatory pathways in developed markets. Following its listing on August 17, 2026, the company is deploying net issue proceeds for automation capex and building an R&D facility in Bengaluru.
What to do with a filing like this
Molbio Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Molbio Diagnostics Limited. Read the original for the full detail.